Nervonik Secures $52.5M for its Intelligent Pain Relief Technology

LOS ANGELES, CA – April 27, 2026 – Nervonik, Inc., a medical device company developing a new generation of smart therapies for chronic pain, has secured an oversubscribed $52.5 million Series B financing round. The funding, led by venture firm Amzak Health, is aimed at accelerating the development and commercialization of the company's novel peripheral nerve stimulation (PNS) system, which uniquely integrates real-time biological sensing to deliver personalized treatment.

The significant investment signals strong confidence in Nervonik's approach to bioelectronic medicine, a field that uses technology to modulate the body's nervous system. The round saw participation from a syndicate of prominent healthcare and tech investors, including Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. This capital infusion will fuel the company's advanced clinical trials and prepare its groundbreaking technology for market entry, offering a new frontier in the fight against chronic neurological conditions.

An Intelligent Leap in Neuromodulation

For years, neuromodulation devices have offered an alternative to pharmaceuticals for chronic pain by using electrical impulses to disrupt pain signals traveling to the brain. However, a common limitation of traditional peripheral nerve stimulation systems is their "open-loop" design. These devices typically deliver a pre-programmed or patient-adjusted level of stimulation without a way to measure the body's direct response, sometimes leading to inconsistent or suboptimal results.

Nervonik aims to solve this fundamental challenge with a closed-loop platform that listens to the body. The company's technology is built to integrate stimulation with advanced sensing, creating a dynamic feedback system. "Nervonik is building a fundamentally differentiated neuromodulation platform that integrates stimulation with advanced sensing to deliver more precise and personalized therapy," said Aydin Babakhani, CEO and Founder of Nervonik.

At the core of this innovation is the system's ability to record what are known as evoked compound action potentials (ECAPs) and other key biomarkers directly from the nerves using its implantable leads. ECAPs are the collective electrical signals generated by a nerve in response to an external stimulus. By measuring these signals in real time, Nervonik's device can gauge the precise effect of its stimulation and automatically adjust its output to maintain an optimal therapeutic dose. This intelligent, adaptive approach promises not only to enhance efficacy but also to reduce the patient's burden of manually adjusting their device, creating a truly personalized treatment experience that evolves with their condition.

A Market at an Inflection Point

The investment in Nervonik comes as the peripheral nerve stimulation market is experiencing a significant surge. Valued at $1.25 billion in 2025, the global market is projected to expand to $2.18 billion by 2035, driven by a desperate search for effective non-opioid pain therapies and growing clinical acceptance of neuromodulation. While established giants like Medtronic, Abbott, and Boston Scientific dominate the current landscape, Nervonik's focus on closed-loop sensing represents a potential paradigm shift that could disrupt the market.

Investors are taking note of this pivotal moment. "Peripheral nerve stimulation is at an inflection point, with expanding clinical evidence and growing adoption in the treatment of chronic pain," commented Anthony Natale, MD, Partner at Amzak Health, the round's lead investor. He emphasized the unique potential of Nervonik's platform, stating, "Aydin and the Nervonik team have developed a highly differentiated technology platform that we believe has the potential to meaningfully improve the patient experience, and they are exceptionally well-positioned to capitalize on this opportunity."

This sentiment reflects a broader industry recognition that the next wave of innovation will come from devices that are not just stimulators, but intelligent systems capable of two-way communication with the body's nervous system.

A Strategic Syndicate of Investors Backs the Future

The $52.5 million financing is more than just capital; it represents a strategic endorsement from a consortium of investors with deep expertise in MedTech, life sciences, and deep-tech innovation. Lead investor Amzak Health has a history of backing "best-in-class" technologies that aim to become the new standard of care. Their leadership in the round validates Nervonik's potential to redefine its category.

The participation of Elevage Medical Technologies, a platform backed by Patient Square Capital, further underscores this confidence. Elevage specializes in funding companies with paradigm-shifting technologies that are moving from clinical development toward commercial launch. Their recent investments, including in neuroimmune modulation therapies, show a clear focus on the future of bioelectronic medicine. Similarly, firms like Lumira Ventures, with its portfolio in novel neuromodulation and pain treatments, and U.S. Venture Partners (USVP), a long-time investor in chronic disease solutions, bring not just money but a wealth of experience in navigating the complex path from lab to patient.

The inclusion of deep-tech investor Foothill Ventures and MedTech-focused Shangbay Capital completes a syndicate that recognizes both the profound technical innovation and the immense clinical and market need for Nervonik's platform. This collective bet suggests a consensus that intelligent, feedback-driven devices are the future of neuromodulation.

Offering New Hope for Millions in Chronic Pain

Beyond the technology and financial figures lies the profound human impact of Nervonik's mission. Chronic pain affects millions of people worldwide, diminishing their quality of life, limiting their ability to work and function, and often leading to a dependency on opioid medications that has fueled a public health crisis. For many, existing treatments offer little relief, leaving them in a cycle of suffering and frustration.

Nervonik's technology directly addresses the core unmet needs of these patients. By creating a more precise and personalized therapy, the platform has the potential to deliver more significant and sustained pain relief than is currently possible. Early results from the company's first-in-human study have already demonstrated the system's ability to adapt to patient-specific physiological signals, hinting at its future effectiveness.

The promise of a non-addictive, highly effective solution that adapts to an individual's unique biology offers a powerful source of hope. For patients who have exhausted other options, a therapy that works with their body to provide consistent relief could mean a return to daily activities, improved mental health, and a life no longer defined by pain. The new funding will allow Nervonik to accelerate its clinical programs and move closer to making this advanced therapy a reality for the patients who need it most.